WuXi AppTec

Global Platform
One Vision

Our Vision

Every Drug Can Be Made
and Every Disease Can Be Treated

By Building an Open-access Platform with the Most Comprehensive Capabilities and Technologies in the Global Healthcare Industry

Our Values

Integrity & Dedication, Working Together & Sharing Success;
Doing the Right Thing, Doing It Right.

About Us

Enabling Innovation

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."

Services and Solutions

An Open Enabling Platform

Enabling more than 6,000 innovative customers from more than 30 Countries

icon

Small Molecule Drug R&D and Manufacturing

icon

Cell Therapy
and Gene Therapy

icon

Drug R&D and Medical
Device Testing

icon

Clinical
Services

icon

Small Molecule Drug R&D and Manufacturing

Company Platform

Enabling Anyone, Any Company

To Become the Most Comprehensive Capability and Technology Platform in the Global Pharmaceutical and Healthcare Industry

WuXi Chemistry

Provides CRDMO services
for new drug development from discovery to commercial

WuXi Biology

A full spectrum of biology services and solutions
supporting stand-alone and integrated projects

WuXi Testing

Seamless drug and medical device testing services
from preclinical testing to clinical trials

WuXi Advanced Therapies

Global CTDMO
offering an integrated end-to-end solution to accelerate time to market for cell and gene therapies

News

The Latest News about WuXi AppTec

WuXi AppTec Maintains AA MSCI ESG Rating for the Fourth Consecutive Year

Despite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up 16.0% QoQ and Adjusted Non-IFRS Net Profit Up 28.5% QoQ

WuXi AppTec Named to the FTSE4Good Index Series for the Second Consecutive Year

WuXi AppTec Breaks Ground on New Site in Singapore to Better Support Global Customers

WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations

WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time

Careers

Welcome to

Our Team

Become Part of Creating a Better Life

Investors

The Latest Financial Reports, Announcements and Resources

【网站舆图】【sitemap】
友情链接:凯时登录·(中国)集团  尊龙凯时 - 人生就是搏!  凯时登录·(中国区)首页  尊龙凯时·(中国区)人生就是搏!  尊龙凯时(中国区)人生就是搏!  尊龙凯时 - 人生就是搏  AG尊龙凯时(中国区)-人生就是搏!  凯时人生就是搏(中国)官方网站